CYCLO THERAPEUTICS INC (CYTH) Stock Overview
USA - NASDAQ:CYTH - US23254X2018 - Common Stock
CYTH Key Statistics, Chart & Performance
The current stock price of CYTH is 0.7206 USD. In the past month the price decreased by -5.31%. In the past year, price decreased by -48.16%.
CYTH Latest News, Press Relases and Analysis
CYTH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.83B | ||
| AMGN | AMGEN INC | 13.35 | 156.75B | ||
| GILD | GILEAD SCIENCES INC | 15.56 | 149.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.8 | 107.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 62.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.73B | ||
| ARGX | ARGENX SE - ADR | 90.1 | 51.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.09 | 34.65B | ||
| INSM | INSMED INC | N/A | 34.67B | ||
| NTRA | NATERA INC | N/A | 26.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.49B | ||
| BIIB | BIOGEN INC | 9.4 | 22.05B |
Related stock screener links
About CYTH
Company Profile
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 8 full-time employees. The company went IPO on 2004-02-27. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The firm is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
Company Info
CYCLO THERAPEUTICS INC
6714 Nw 16Th Street, Suite B
Gainesville Florida FLORIDA 32653 US
CEO: N. Scott Fine
Employees: 8
Phone: 13864188060
CYCLO THERAPEUTICS INC / CYTH FAQ
What does CYCLO THERAPEUTICS INC do?
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 8 full-time employees. The company went IPO on 2004-02-27. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The firm is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
What is the stock price of CYCLO THERAPEUTICS INC today?
The current stock price of CYTH is 0.7206 USD. The price increased by 1.39% in the last trading session.
What is the dividend status of CYCLO THERAPEUTICS INC?
CYTH does not pay a dividend.
What is the ChartMill rating of CYCLO THERAPEUTICS INC stock?
CYTH has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for CYTH stock?
CYCLO THERAPEUTICS INC (CYTH) currently has 8 employees.
Can you provide the market cap for CYCLO THERAPEUTICS INC?
CYCLO THERAPEUTICS INC (CYTH) has a market capitalization of 23.72M USD. This makes CYTH a Nano Cap stock.
CYTH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CYTH. When comparing the yearly performance of all stocks, CYTH is a bad performer in the overall market: 63.48% of all stocks are doing better.
CYTH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYTH. CYTH has a bad profitability rating. Also its financial health evaluation is rather negative.
CYTH Financial Highlights
Over the last trailing twelve months CYTH reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 44.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -472.02% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYTH Forecast & Estimates
9 analysts have analysed CYTH and the average price target is 0.97 USD. This implies a price increase of 34.47% is expected in the next year compared to the current price of 0.7206.
For the next year, analysts expect an EPS growth of 56.84% and a revenue growth -41.47% for CYTH